DBF4-type zinc finger-containing protein 2 (ZDBF2)

Homo sapiens — UniProt Q9HCK1

Gene: ZDBF2Homo sapiensSwissProt reviewed

Data last refreshed: 2026-04-18 (UniProt release unknown)

Key facts

DBF4-type zinc finger-containing protein 2 (ZDBF2) is a protein from Homo sapiens identified by UniProt accession Q9HCK1, 2354 residues long. MolForge cross-references it against 0 known binders and 29 disease associations.

UniProt accession: Q9HCK1; gene symbol ZDBF2.
Organism: Homo sapiens.
Length: 2354 amino acids.
Top disease associations (Open Targets): body mass index, age at menarche and neurodegenerative disease.
3D structure: AlphaFold model available.

Target properties

Protein name	DBF4-type zinc finger-containing protein 2
UniProt accession	Q9HCK1
Gene	ZDBF2
Organism	Homo sapiens
Length	2354 residues
Molecular weight	—
EC numbers	—
Target class	—
Subcellular location	—
Keywords	—

Druggability

Target tractability assessment (Open Targets + pocket analysis). No approved drug

Druggability tier	MEDIUM
Druggability score	—
Pocket score	—
Max clinical phase	—

Disease associations (29)

Diseases linked to this target (Open Targets).

body mass index · score 0.41
age at menarche · score 0.34
neurodegenerative disease · score 0.26
nasopalpebral lipoma-coloboma syndrome · score 0.12
breast ductal adenocarcinoma · score 0.11
tooth agenesis · score 0.09
transient myeloproliferative syndrome · score 0.05
health study participation · score 0.05
pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 9 · score 0.04
reticular dysgenesis · score 0.03

3D Structure (1)

Experimental (PDB) and predicted (AlphaFold) structures for this protein.

Structure	Source	Method	Mean pLDDT	Resolution (Å)
AF-Q9HCK1-F1	alphafold	PREDICTED	34.57	—

Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9HCK1.

Amino-acid sequence (2354 residues)

MQKRQGYCSY CRVQYNNLEQ HLFSAQHRSL TRQSRRQICT SSLMERFLQD VLQHHPYHCQ ESSSTQDETH VNTGSSSEVV HLDDAFSEEE EEDEDKVEDE DATEERPSEV SEPIEELHSR PHKSQEGTQE VSVRPSVIQK LEKGQQQPLE FVHKIGASVR KCNLVDIGQA TNNRSNLVRP PVICNAPASC LPESSNDRPV TANTTSLPPA AHLDSVSKCD PNKVEKYLEQ PDGASRNPVP SSHVETTSFS YQKHKESNRK SLRMNSDKLV LWKDVKSQGK TLSAGLKFHE RMGTKGSLRV KSPSKLAVNP NKTDMPSNKG IFEDTIAKNH EEFFSNMDCT QEEKHLVFNK TAFWEQKCSV SSEMKFDCIS LQSASDQPQE TAQDLSLWKE EQIDQEDNYE SRGSEMSFDC SSSFHSLTDQ SKVSAKEVNL SKEVRTDVQY KNNKSYVSKI SSDCDDILHL VTNQSQMIVK EISLQNARHI SLVDQSYESS SSETNFDCDA SPQSTSDYPQ QSVTEVNLPK EVHIGLVDKN YGSSSSEVSA DSVFPLQSVV DRPPVAVTET KLRKKAHTSL VDNYGSSCSE TSFDCDVSLE SVVDHPQLTV KGRNLKGRQV HLKHKKRKPS SAKAHLDCDV SLGTVADESQ RAVEKINLLK EKNADLMDMN CESHGPEMGF QADAQLADQS QVAEIERQKV DVDLENKSVQ SSRSSLSSDS PASLYHSAHD EPQEALDEVN LKELNIDMEV RSYDCSSSEL TFDSDPPLLS VTEQSHLDAE GKERHIDLED ESCESDSSEI TFDSDIPLYS VIDQPEVAVY EEETVDLESK SNESCVSEIT FDSDIPLHSG NDHPEVAVKE VIQKEEYIHL ERKNDEPSGS EISSDSHAPL HSVTNSPEVA VKKLNPQKEE QVHLENKENE PIDSEVSLDY NIIFHSVTGR SEDPIKEISL HTKEHMYLEN KSVFETSLDS DVPLQAATHK PEVIVKETWL QREKHAEFQG RSTEFSGSKT SLDSGVPHYS VTEPQVAVNK INRKKQYVLE NKNDKCSGSE IILDSNVPPQ SMTDQPQLAF LKEKHVNLKD KNSKSGDSKI TFDSEQLQEA VKKIDQWKEE VIGLKNKINE PSTYKLIHHP DVSVQSVADQ PKVAIKHVNL GNENHMYLEV KNSQYSCSEM NLDSGFLGQS IVNRPQITIL EQEHIELEGK HNQCCGSEVS FDSDDPLQSV ADRLRETVKE ISLWKDEEVD TEDRRNEAKG FEIMYDSDVL QPVAGQPEEV VKEVSLWKEH VDLENKIVKP TDSRINFDSH EPLQSVTNKI PGANKEINLL REEHVCLDDK GYVPSDSEII YVSNIPLQSV IKQPHILEEE HASLEDKSSN SYSPEESSDS NDSFQAAADE LQKPVKEINL WKEDHIYLED KSYKLGDFDV SYASHIPVQF VTDQSSVPVK EINLQKKDHN DLENKNCEVC GSEIKCHSCV HLQSEVDQPQ VSYKEADLQK EEHVVMEEKT DQPSDSEMMY DSDVPFQIVV NQFPGSVKET HLPKVVLVDL VPGDSDYEVI SDDIPLQLVT DPPQLTVKDI SCINTECIDI EDKSCDFFGS EVRCNCKAST PSMTNQCKET FKIINRKKDY IILGEPSCQS CGSEMNFNVD ASDQSMTYES QGPDEKMVKY IDSEDKSCGY NGSKGKFNLE DTSHRTTHRL QKAHKEASLR KDPRNAGLKG KSCQSSASAV DFGASSKSAL HRRADKKKRS KLKHRDLEVS CEPDGFEMNF QCAPPLPSDT DQPQETVKKR HPCKKVSSDL KEKNHDSQSS SVLKVDSVRN LKKAKDVIED NPDEPVLEAL PHVPPSFVGK TWSQIMREDD IKINALVKEF REGRFHCYFD DDCETKKVSS KGKKKVTWAD LQGKEDTAPT QAVSESDDIV CGISDIDDLS VALDKPCHRH PPAERPPKQK GRVASQCQTA KISHSTQTSC KNYPVMKRKI IRQEEDPPKS KCSRLQDDRK TKKKVKIGTV EFPASCTKVL KPMQPKALVC VLSSLNIKLK EGEGLPFPKM RHHSWDNDIR FICKYKRNIF DYYEPLIKQI VISPPLSVIV PEFERRNWVK IHFNRSNQNS SAGDNDADGQ GSASAPLMAV PARYGFNSHQ GTSDSSLFLE ESKVLHAREL PKKRNFQLTF LNHDVVKISP KSVRNKLLES QSKKKIHGKR VTTSSNKLGF PKKVYKPIIL QQKPRKASEK QSIWIRTKPS DIIRKYISKY SVFLRHRYQS RSAFLGRYLK KKKSVVSRLK KAKRTAKVLL NSSVPPAGAE ELSSAMANPP PKRPVRASCR VARRRKKTDE SYHGRQKGPS TPVRAYDLRS SSCLQQRERM MTRLANKLRG NEVK

External references

UniProt AlphaFold QuickGO RCSB PDB GeneCards

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

Which diseases are associated with ZDBF2?

The strongest Open Targets associations for ZDBF2 are body mass index, age at menarche, neurodegenerative disease, nasopalpebral lipoma-coloboma syndrome and breast ductal adenocarcinoma.

How long is the ZDBF2 protein?

The Homo sapiens ZDBF2 protein (UniProt Q9HCK1) is 2354 amino acids long.

Browse: Targets: Z · all protein targets A–Z · drugs A–Z.

Sources

UniProtKB Q9HCK1 — name, gene, function, sequence, keywords (CC BY 4.0)
AlphaFold DB Q9HCK1 — predicted 3D structure (CC BY 4.0)
Open Targets Platform — disease associations and tractability (CC0)

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.